Design and Characterization of Recombinant and Chimeric BoNT/A Neurotoxins with Receptor-Binding Domain Grafting
Open Access
Abstract
Botulinum neurotoxins (BoNTs) act on peripheral cholinergic nerve terminals, inducing reversible muscle paralysis and profound therapeutic effects. However, their limited cell-type specificity and narrow therapeutic window have motivated the development of engineered variants. Here, a modular strategy was employed to construct full-length chimeric BoNTs, grafting receptor-binding segments from BoNT/B or BoNT/F onto the BoNT/A framework. The novel chimeras AAAF and AAFF efficiently cleaved rSNAP-25 in cell-free assays. Firstly, both toxins showed effective cellular uptake and cleaved endogenous SNAP-25 in Neuro-2a cells, with cleavage efficiencies of approximately 46% for AAAF and 73% for AAFF, highlighting the enhanced activity of AAFF. Secondly, AAAF induced faster recovery from reversible muscle paralysis compared to rBoNT/A-WT, whereas AAFF produced more sustained paralysis, with both exhibiting reduced systemic toxicity. Despite these altered pharmacological profiles, the chimeras required higher doses than rBoNT/A-WT to induce neuromuscular effects. Collectively, this study presents the design of novel chimeric BoNT/A-F proteins, characterizes their functional activities, and provides a preliminary exploration of how domain grafting affects cellular uptake, enzymatic activity, and neuromuscular pharmacodynamics.Keywords
Funding Information
- Key Areas Research and Development Program of Guangdong Province (2024B1111160006)
This publication has 45 references indexed in Scilit:
- Botulinum toxin therapy: past, present and future developmentsJournal of Neural Transmission, 2022
- Recombinant botulinum neurotoxin serotype A1 in vivo characterizationPharmacology Research & Perspectives, 2021
- The Structure and Classification of Botulinum Toxins2019
- A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic painNeuropharmacology, 2017
- BoNT/AB hybrid maintains similar duration of paresis as BoNT/A wild-type in murine running wheel assayNeuroToxicology, 2017
- Historical and current perspectives on Clostridium botulinum diversityResearch in Microbiology, 2015
- Fusion protein linkers: Property, design and functionalityAdvanced Drug Delivery Reviews, 2013
- OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled TrialJournal of Urology, 2013
- Presynaptic Neurotoxins with Enzymatic Activities2008
- Evaluation of GRAMM low-resolution docking methodology on the hemagglutinin-antibody complexProteins: Structure, Function, and Bioinformatics, 1997